156 related articles for article (PubMed ID: 35093003)
21. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
[TBL] [Abstract][Full Text] [Related]
23. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
25. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; Yu J; Borel Rinkes IHM; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Eur J Surg Oncol; 2019 Sep; 45(9):1674-1683. PubMed ID: 31023560
[TBL] [Abstract][Full Text] [Related]
26. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
Miyasaka Y; Ohtsuka T; Eguchi S; Inomata M; Nishihara K; Shinchi H; Okuda K; Baba H; Nagano H; Ueki T; Noshiro H; Nakamura M;
Int J Surg Protoc; 2021 Apr; 25(1):55-60. PubMed ID: 34013145
[TBL] [Abstract][Full Text] [Related]
29. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
[TBL] [Abstract][Full Text] [Related]
30. Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.
Kharofa J; Mierzwa M; Olowokure O; Sussman J; Latif T; Gupta A; Xie C; Patel S; Esslinger H; Mcgill B; Wolf E; Ahmad SA
Am J Clin Oncol; 2019 Mar; 42(3):247-252. PubMed ID: 30724781
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Carcinoma Followed by Pancreatectomy with Portal Vein Resection and Reconstruction with Venous Allograft.
Huang JC; Pan B; Wang HX; Chen Q; He Q; Lyu SC
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555996
[TBL] [Abstract][Full Text] [Related]
32. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
Maeda S; Moore AM; Yohanathan L; Hata T; Truty MJ; Smoot RL; Cleary SP; Nagorney DM; Grotz TE; Park EJ; Girgis MD; Reber HA; Motoi F; Masuda T; Unno M; Kendrick ML; Donahue TR
Surgery; 2020 May; 167(5):803-811. PubMed ID: 31992444
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer.
Cho IR; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Hwang HK; Kang CM; Lee WJ; Park JY
Pancreatology; 2013; 13(5):539-43. PubMed ID: 24075521
[TBL] [Abstract][Full Text] [Related]
34. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
35. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
36. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
37. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for borderline-resectable pancreatic cancer.
Okamura Y; Nishitai R; Sasaki N; Ito H; Sakamoto T; Itokawa Y; Kusumoto M; Nakai Y; Yamaoka T; Manaka D
Asia Pac J Clin Oncol; 2024 May; ():. PubMed ID: 38771310
[TBL] [Abstract][Full Text] [Related]
39. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.
Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444
[TBL] [Abstract][Full Text] [Related]
40. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial.
Okada K; Kawai M; Hirono S; Satoi S; Yanagimoto H; Ioka T; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
Cancer Chemother Pharmacol; 2016 Oct; 78(4):719-26. PubMed ID: 27501851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]